Abstract
In order to evaluate the efficacy and safety of concurrent CBDCA or CDDP and radiotherapy, previously untreated 33 T2N0 glottic carcinomas were treated with CBDCA at 100mg/m2 once a week or CDDP at 4mg/m2 four times a week given simultaneously for the conventional radiotherapy (2.5Gy×4/week) from November 1990. At the dose of 40Gy, patients were evaluated. NC cases underwent planned surgery and PR + CR cases continued this modality up to a dose of 65Gy. Kaplan-Meier 5-year overall survival rate was 88.1%. Toxicity was greater in the patients concurrent with a higher incidence of grade III neutropenia, thrombocytopenia, dermatitis. No toxic deaths occurrerd. We compared a results of this concurrent chemoradiotherapy to historical control consisted of 15 radiotherapy alone cases from 1988 to 1990. The result of the study shows advantage in terms of overall survival (p=0.04), but no advantage in overall survival with successful laryngeal preservation.
